There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown ... and potentially a replacement for checkpoint inhibitor standard-of-care treatments for a range of ...

Immune checkpoint inhibitors, a class of immunotherapies that help immune cells attack cancer more effectively, have revolutionized cancer treatment. However, fewer than 20% of patients respond to ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by ...

Immune checkpoint inhibitors, a class of immunotherapies that help immune cells attack cancer more effectively, have ...

Cerevance's solengepras failed to meet its primary endpoint in the ASCEND trial, which sought to evaluate it as a monotherapy ...

First VISTA Inhibitor Drug Approval By 2028 Says Kuick Research In New Research Publication. Delhi, April 02, 2025 (GLOBE ...

CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflam ...

Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials ...

Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

Scholar Rock Holding Corporation’s SRRK share price has dipped by 12.38%, which has investors questioning if this is right ...

In March 2025, Coordination Pharmaceuticals Inc. announced a phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or ...